|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 306.80 SEK | +0.59% |
|
-3.82% | -1.29% |
| 06/02 | Bioarctic reports Q4 sales of Leqembi at yen 20.7 billion | RE |
| 06/02 | Bioarctic's Royalty from Leqembi Sales Rises 31 Percent in Fourth Quarter | FW |
Main competitors
| 1m. Revenue rev. | 4m. EPS revision | 4m. Revenue rev. | 1y. EPS revision | 1y. Revenue rev. | Visibility | Nbr of analysts | ||
|---|---|---|---|---|---|---|---|---|
| 5 | ||||||||
| 23 | ||||||||
| 24 | ||||||||
| 22 | ||||||||
| 20 | ||||||||
| 19 | ||||||||
| 12 | ||||||||
| 15 | ||||||||
| 22 | ||||||||
| 16 | ||||||||
| 16 | ||||||||
| 14 | ||||||||
| 11 | ||||||||
| 12 | ||||||||
| Average | 16 | |||||||
| Weighted average by Cap. | 19 |
- Stock Market
- Equities
- BIOA B Stock
- Sector BioArctic AB
- Sector revisions
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















